Saturday 17 October 2026
Export SDGR’s income statement to Excel — free account
Schrodinger, Inc.
SDGR Healthcare Health Information Services
Schrodinger, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $255.9 million, up 23.3% from fiscal 2024. In the quarter to June 2026, revenue grew 7.54%, EPS grew 113.6% and free cash flow grew 34.4%, each against the same quarter a year earlier.
22.60
2.88
−11.30%
Follow SDGR
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
4.69 | 3.30 | 5.13 | 5.75 | |
P/FCF ratio |
0.00 | 0.00 | 105.42 | 0.00 | |
P/Operating CF |
(35.64) | (56.66) | (81.60) | (23.87) | |
P/B ratio |
3.69 | 2.68 | 3.61 | 4.60 | |
Price to Tangible BV |
3.75 | 2.72 | 3.66 | 4.66 | |
EV/Sales |
3.07 | 1.70 | 3.56 | 4.19 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(6.27) | (2.99) | 65.53 | (959.58) | |
EV/FCF |
(6.10) | (2.93) | 73.12 | (316.85) | |
Quick Ratio |
2.65 | 2.68 | 2.68 | 3.16 | |
Current Ratio |
2.71 | 2.74 | 2.75 | 3.25 | |
Net Debt/EBITDA |
10.45 | 8.59 | 25.59 | 9.01 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.39 | 0.37 | 0.33 | 0.39 | |
Operating CF/Net income |
(5.70) | 0.25 | (0.49) | 1.89 | |
Capex/Depreciation |
(0.24) | (1.70) | (0.03) | (0.34) | |
Research and Development Expense of Revenue |
69.62% | 74.80% | 47.46% | 78.71% | |
Selling, General and Administrative Expense of Revenue |
56.01% | 58.92% | 37.89% | 57.49% | |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.01 | 0.01 | |
Share Based Compensation of Revenue |
14.93% | 15.49% | 11.41% | 19.97% | |
Graham Net Nets |
0.13 | 0.17 | 0.12 | 0.09 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(4.55%) | (12.41%) | (7.94%) | (12.01%) | |
Free Cash Flow Yield |
(10.73%) | (17.65%) | 0.95% | (0.23%) | |
Revenue per Share |
0.79 | 0.79 | 1.19 | 0.74 | |
Operating CF per Share |
(0.46) | (0.20) | (0.22) | (0.84) | |
Capex per Share |
0.00 | (0.03) | 0.00 | (0.01) | |
Free Cash Flow per Share |
(0.46) | (0.23) | (0.22) | (0.85) | |
Cash per Share |
5.61 | 5.49 | 5.48 | 5.45 | |
Shareholders Equity per Share |
4.40 | 4.24 | 4.96 | 4.37 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
4.40 | 4.24 | 4.96 | 4.37 | |
Free Cash Flow |
(34.43) | (17.34) | (16.13) | (62.36) | |
Working Capital |
296.63 | 294.42 | 330.13 | 326.61 | |
Capital Expenditures |
(0.36) | (2.51) | (0.04) | (0.49) | |
Net Current Asset Value |
159.04 | 143.32 | 157.16 | 139.41 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.04 | 0.00 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
38.95 | 47.25 | 179.86 | 51.11 | |
Average Payables |
9.56 | 11.90 | 11.06 | 10.21 | |
Average Assets |
664.32 | 688.61 | 774.69 | 661.48 | |
Average Common Equity |
335.91 | 343.53 | 392.75 | 385.39 |
Columns are period end dates